Welcome to Dr. Elliott Antman's AHA Emerging Science™ Series.
 

AHA is proud to introduce a new program to further science collaboration hosted by Dr. Elliot Antman: The AHA Emerging Science™ Series webinars are one hour professional quality webinars held three times per year. Dr. Antman will host each webinar, which will have two 30 minute blocks, consisting of presentations of original research from the following categories:

std_Portrait%20Antman11.jpg
  • Late Breaking Clinical Trials
  • Clinical Trial Updates of previously presented LBCTs
  • Late Breaking Basic Science
  • Major Bench-to-Bedside Advances
  • Major Conference Proceedings
  • Major Guidelines/Policy Statements

The live webinar events will be viewable from a computer or mobile phone, both live and on-demand. Attendees can ask questions electronically during the live event or post event. 

Join us at the next event, or view for past events by visiting the Emerging Science Series page on Professional Heart Daily.

Latest Posts

  • International Stroke Conference 2017
    I have attended the International Stroke Conference (ISC) every year since my third year of residency in 2013. It is by far the most educational and most fun conference for me as a stroke neurologist. This is the premiere conference for stroke and most of the groundbreaking trials are presented here. I remember the ISC 2015 in Nashville where several of ... more...
  • Cardiovascular Research and Care in the Era of Big Data
    Ten years ago, I made a decision that had a profound and lasting impact on my career. I decided to take time off, in the midst of grad school, and learn introductory computer programming. This was already several years after the initial draft sequence of the human genome had been released, and big data was starting to permeate virtually every research ... more...
  • Wake-up Strokes
    Strokes continue to be the leading cause of long term disability. One of the primary reasons for this is a short time window acutely where patients are eligible for IV thrombolysis. Endovascular intervention increases the time window. Large proportions of patients with stroke do not make it to the hospital within this treatment window. When ... more...
  • Community Engagement
    As a Cardiologist in-training—and concerned physician, in general—I think it’s a good idea to stop every once in a while, to consider some of the ways we might engage our communities through our careers. After all, the walls of a hospital or clinic certainly aren’t the bounds of the care we provide. In many regards, our mission only starts there!   Being ... more...
  • Lead-Based Masses: An Iatrogenic Challenge No One Saw Coming!
    Cardiac implantable electronic devices (CIEDs) have undergone tremendous changes over the years. Since the days of Hyman, they have undergone transformation from backups in emergencies to dependable workmen. In keeping with the same transformation, an entirely new treatment modality (cardiac resynchronization devices) emerged. Expected ... more...

Most Recent Comments

I am intrigued by this exciting new AHA Emerging Science Series, and particularly interested to hear the discussion on the US subgroup analysis from PLATO.
I am very enthusiastic to hear more about tissue engineered vascular grafts. The science is quite provocative and the potential for clinical application is substantial!
As the Director of the Adult Invasive and Interventional Cardiology Program in Nassau, The Bahamas, I am excited to join the panel to discuss the implications of the PLATO US subgroup findings. Clearly dual antiplatelet therapy is at the center of the pharmacologic support for PCI and we need to understand the optimal regimen to protect our patients.
I am pleased to see a translational science presentation in this first webinar of the AHA Emerging Science Series. Using allogeneic fibroblasts to build a tissue engineered vascular graft is a creative approach to a common clinical problem. I look forward to learning more about how this was done and the results in the first in human experience.
The PLATO US substudy raises a number of important questions that will attract the attention of clinical trialists, interventional cardiologists, and vascular biologists. Should be an interesting discussion.